Egypt. J. Chem. **Vol. 68**, No. 2. pp. 135 –144 (2025)

Egyptian Journal of Chemistry

http://ejchem.journals.ekb.eg/

An Updated Review about Pain Management Medications and Biochemical Mechanisms-Overview for Healthcare Professionals

Ayman Mohammed Mukui[1], Alwaleed Ali Bishi[1], Badria Hussain Ali Ghazwani[1], Turki Mohammed Alnasyan[2], Bandar Naji Alkhaibari[3], Ali Yahya Sharahili[4], Nourah Ali Abdullah Almassari Aldosari[3], Sami Khaled Al-Anzi[5], Mishaal Atiq Al-Anzi[5], Faris Abdullah Al-Anzi[5], Nada Ali Alkhybari[6]

[1] Northern Area Armed Forces Hospital, Ministry of defense, Saudi Arabia
[2] Prince Sultan Air Base hospital, Ministry of defense, Saudi Arabia
[3] Prince Sultan Military Medical City, Ministry of defense, Saudi Arabia
[4] Prince Sultan Cardiac Center, Ministry of defense, Saudi Arabia
[5] Ministry of defense, Saudi Arabia
[6] Elkharg region, Ministry of defense, Saudi Arabia

Abstract

Background: Pain, as defined by the International Association for the Study of Pain (IASP), is an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Despite ongoing debates about revising this definition, pain management remains a critical aspect of healthcare, with pharmacological agents categorized into nonopioid and opioid analgesics. Nonopioid agents, such as acetaminophen and NSAIDs, are used for mild to moderate pain, while opioids are reserved for severe pain due to their potent effects on the central nervous system. However, opioids carry significant risks, including addiction and adverse effects, necessitating careful monitoring and patient selection.

Aim: This review aims to provide an updated overview of pain mechanisms, biochemical pathways, and management strategies, focusing on the mechanisms of action, administration, adverse effects, contraindications, monitoring, and toxicity of nonopioid and opioid analgesic agents. It also emphasizes the importance of a multidisciplinary approach to optimize patient outcomes.

Methods: The review synthesizes current evidence and guidelines on pain management, including the pharmacological properties, therapeutic uses, and risks associated with nonopioid and opioid analgesics. It also discusses the role of interprofessional collaboration in enhancing pain management outcomes.

Results: Nonopioid analgesics, such as acetaminophen, NSAIDs, antidepressants, and antiepileptics, are effective for mild to moderate pain and neuropathic conditions. Opioids, while effective for severe pain, pose risks of addiction, tolerance, and adverse effects, requiring careful patient monitoring. Multidisciplinary collaboration, including pharmacists, nurses, and mental health professionals, is essential for optimizing pain management and minimizing risks.

Conclusion: Pain management requires a tailored, evidence-based approach that balances efficacy and safety. Nonopioid agents are preferred for mild to moderate pain, while opioids should be used cautiously for severe pain. Interprofessional collaboration and patient education are crucial for improving outcomes and reducing the risks of misuse and addiction.

Keywords: Pain management, nonopioid analgesics, Biochemical Pain Mechanism, opioid analgesics, adverse effects, interprofessional collaboration, toxicity, monitoring.

1. Introduction

The International Association for the Study of Pain (IASP) characterizes pain as an unpleasant sensory and/or emotional experience linked to actual or potential tissue damage or described in such terms [1]. This definition has sparked ongoing debate about whether it requires revision to better reflect the complexities of pain as a multifaceted phenomenon [2][3][4]. Nevertheless, the classification of pharmacological agents for pain management remains well-established, with medications primarily divided into two categories: nonopioid and opioid analgesic agents. Nonopioid analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), are typically used for mild to moderate pain and have mechanisms centered on inhibiting prostaglandin synthesis or modulating neurotransmitter activity. Opioid analgesics, on the other hand, are reserved for severe pain due to their potent effects on the central nervous system, primarily through mu-opioid receptor agonism. Despite their efficacy, opioids are associated with significant risks, including addiction, tolerance, and adverse effects, necessitating careful patient selection and monitoring. This classification framework provides a structured approach to pain management, enabling healthcare providers to tailor treatments based on pain severity, patient history, and risk factors. While the debate over the IASP definition continues, the pharmacological categorization of pain management agents remains a cornerstone of clinical practice, ensuring a systematic and evidence-based approach to alleviating pain.

*Corresponding author e-mail ayman.mukui@gmail.com (Ayman Mohammed Mukui)
Receive Date: 03 December 2024, Revise Date: 23 January 2025, Accept Date: 23 January 2025
DOI: 10.21608/ejchem.2025.340884.10925

Biochemical Mechanisms of Pain:
Pain and Nociceptors:

Living organisms must effectively identify and respond to harmful stimuli from their external environment, a critical function facilitated by nociceptors, which are integral components of the somatosensory nervous system. These specialized receptors detect and transmit signals from harmful or potentially damaging stimuli originating in the skin, muscles, joints, and viscera. Nociceptors are categorized based on their axon characteristics, primarily divided into unmyelinated C fibers and slightly myelinated Aδ fibers. The cell bodies (soma) of nociceptors are typically small in diameter, found in the dorsal pathway and other sensory ganglia. Neurons with small soma diameters generally possess either myelinated Aδ fibers or unmyelinated C fibers, whereas larger cells may feature Aα/β fibers. Importantly, soma size and axon myelination do not influence nociceptor functionality. For instance, non-visceral nociceptors have smaller soma compared to visceral nociceptors, yet this size difference does not affect their functional capacity [5].

Nociceptor activation is determined by the nature, location, and intensity of the pain stimulus. The site of stimulus application significantly influences the nociceptor response, as demonstrated by corneal nociceptors, which respond to weaker stimuli compared to skin nociceptors. The type of stimulus also plays a crucial role. For example, mechanical forces such as cutting or crushing activate skin nociceptors but not those in joints, muscles, or viscera, which instead respond to stimuli like rotation or distention. Skin nociceptors, the most abundant in the body, are activated by a variety of harmful stimuli, including chemical, thermal, and mechanical damage. The skin predominantly contains polymodal nociceptors, which respond to multiple types of stimuli. However, it also hosts a diverse array of nociceptors with specific sensitivities, such as C-heat and C-mechano-cold nociceptors. In other tissues, nociceptors primarily detect chemical changes (e.g., pH shifts or inflammation) and mechanical forces (e.g., torque or distention). Studies on joint nociceptors reveal subpopulations are sensitive to both low- and high-intensity mechanical stimuli, many of which are polymodal. These nociceptors transduce harmful stimuli and sensitize the organism, with low-threshold afferents contributing to pain during tissue inflammation. Mechanonociceptors, activated solely by mechanical stimuli, and polymodal nociceptors, responsive to additional stimuli like heat or cold, further illustrate the diversity of nociceptor subpopulations [5].

The transient receptor potential (TRP) channels, a large family of receptors, play a pivotal role in nociception. This family includes six subfamilies: TRPV, TRPA, TRPML, TRPP, TRPC, and TRPM. TRPV1 receptors, expressed on C-fiber nociceptors, detect noxious heat and mediate heat hyperalgesia, while TRPA1 receptors respond to inflammatory factors and calcium. TRPM8 receptors are associated with noxious cold detection and menthol sensitivity. Additionally, C-fiber nociceptors expressing Mas-related G-protein-coupled receptor D transduce blunt mechanical stimuli, whereas A-fiber mechanonociceptors detect sharp, tissue-damaging stimuli. The anoctamin 1 (ANO1) receptor, a calcium-activated chloride channel, is also involved in nociception, particularly in response to noxious heat. Piezo channels, comprising Piezo1 and Piezo2, are mechanosensitive receptors that mediate somatic and visceral pain in response to various mechanical stimuli. Sensitization is a hallmark property of nociceptors, characterized by increased neuronal excitability, reduced activation thresholds, and heightened response rates to harmful stimuli. This process typically results from tissue injury or inflammation and can render previously ineffective stimuli capable of eliciting a response. Sensitization is not exclusive to nociceptors but is also observed in afferents encoding other sensory modalities. It plays a critical role in the adaptive response to prolonged stimuli [5].

Certain nociceptors, particularly peptidergic nociceptors, possess efferent functions, enabling them to release substances from their peripheral terminals. This capability helps maintain tissue integrity even in the absence of damage. For example, nociceptive nerves collaborate with sympathetic nerves to regulate hematopoietic stem cell (HSC) mobilization and maintenance in bone. Neurogenic inflammation, often associated with conditions like migraines, arises from increased peripheral release of afferent transmitters during sterile inflammation. The release of molecules from nociceptors is not solely linked to inflammation but also contributes to pain perception during tissue damage. The inhibition of voltage-gated Ca2+ and Na+ channels, which mediate peripheral transmitter release, can alleviate neurogenic inflammation and pain. Nociceptors exhibit significant anatomical, biochemical, physiological, and functional heterogeneity, making them a diverse group of afferents. This diversity complicates the development of therapeutic agents, as targeting specific nociceptor subpopulations remains challenging. Visceral nociceptors, for instance, contribute to sensations like organ filling hypersensitivity, acidic or burning pain, and bloating. Overcoming this heterogeneity is essential for advancing pain treatment strategies and addressing the limitations of current therapies [5].



Figure 1: Pain and Nociceptors.

Pain and Inflammatory Cytokines:

Cytokines, particularly those released by immune cells during inflammatory processes, play a pivotal role in modulating nociceptor activity and contributing to pain sensitization. Among these, interleukin-1β (IL-1β) was the first cytokine identified for its hyperalgesic properties, marking a significant milestone in neuroimmunology by demonstrating that immune-derived molecules can induce neuronal sensitization. This discovery also highlighted that blocking the IL-1β receptor can mitigate hyperalgesia, underscoring the therapeutic potential of cytokine modulation in pain management. Cytokines have been implicated in the pathophysiology of various conditions, including arthritis, neuropathic pain, and cancer-related pain, further emphasizing their role in pain modulation. IL-1β, IL-6, tumor necrosis factor-alpha (TNF-α), IL-17A, and interleukin-5 (IL-5) directly influence nociceptor neurons, contributing to pain sensitization. IL-1β enhances nociceptor sensitivity through the phosphorylation of p38 mitogen-activated protein kinases (MAPK) on Nav1.8 sodium channels, leading to increased action potential generation and resulting in mechanical and thermal hyperalgesia. Additionally, IL-1β enhances thermal pain sensitivity by activating interleukin-1 receptor type 1 (IL-1R1) on nociceptors, which upregulates the expression of transient receptor potential vanilloid 1 (TRPV1) [5].

IL-6 exacerbates inflammatory pain by stimulating prostaglandin production and increasing the expression of TRPV1 and transient receptor potential ankyrin 1 (TRPA1) through its receptor gp130, which is present on nociceptors. Similarly, TNF-α contributes to inflammatory pain by interacting with tumor necrosis factor receptor 1 and promoting prostaglandin synthesis. TNF-α also influences nociceptor sensitivity by phosphorylating p38 MAPK on Nav1.8 and Nav1.9 sodium channels, thereby altering neuronal excitability. Collectively, these findings demonstrate that IL-1β, IL-6, and TNF-α enhance nociceptor sensitization by promoting prostaglandin synthesis and modulating TRP and sodium channel activity. IL-17A, a cytokine prominently expressed in nociceptive neurons, plays a significant role in autoimmune diseases such as arthritis and psoriasis. It rapidly increases neuronal excitability, contributing to the pain associated with these conditions. IL-17A-induced hyperalgesia is mediated by the amplification of TNF-α, IL-1β, chemokine (C-X-C motif) ligand 1 (CXCL1), endothelin-1, and prostaglandins, particularly in antigen-induced arthritis. This cytokine's involvement in autoimmune pain pathways highlights its potential as a therapeutic target for managing pain in autoimmune disorders. In summary, cytokines such as IL-1β, IL-6, TNF-α, and IL-17A are critical mediators of nociceptor sensitization and pain amplification. Their ability to modulate ion channels, prostaglandin synthesis, and neuronal excitability underscores their central role in inflammatory and autoimmune pain pathways, offering valuable insights for developing targeted pain therapies [5].



Figure 2: Cytokines and Pain.

Immune System and Pain:

Pain mediated by nociceptive neurons is significantly influenced by the immune system through the release of molecular mediators that sensitize nociceptors, amplifying the sensation of pain. During inflammation, these mediators are released and detected by nociceptors on peripheral nerve terminals. Additionally, soluble mediators such as calcitonin gene-related peptide, substance P, bradykinin, and nitric oxide are secreted, contributing to edema, hyperemia, and the recruitment of immune cells. These vascular changes facilitate the invasion of circulating immune cells, which further release molecular mediators, perpetuating the inflammatory response. Upon activation, nociceptors transduce action potentials to their cell bodies in the dorsal root ganglia (DRG), which relay the stimuli to the spinal cord and brain for processing as pain. During inflammation, the threshold for nociceptor activation is reduced, leading to heightened pain sensitivity, or hyperalgesia. Central glia, including microglia and astrocytes, respond to peripheral injury through afferent nerve input, circulating cytokines, and interactions with immune cells. Glial activation is consistently observed in deep tissue injuries, such as those affecting muscles, joints, nerve trunks, and viscera, with glial hyperactivity directly correlating with inflammatory injury and pain intensity. Glia selectively promote sensitization following injury, with their responses varying depending on the type of nociceptive input. Proinflammatory cytokines, such as interleukin-6 (IL-6), act as messengers, transmitting peripheral immune signals to the central nervous system by inducing cyclooxygenase-2 (COX-2) activity and prostaglandin E2 (PGE2) release. Peripheral macrophages and monocytes migrate into the spinal cord, differentiating into microglia-like cells that contribute to central glial responses. Upon nociceptive nerve impulse arrival, neural and immune mediators, including glutamate, ATP, substance P, calcitonin gene-related peptide, brain-derived neurotrophic factor (BDNF), IL-6, and C-C motif chemokine ligand 2 (CCL2),

are released. These mediators act on postsynaptic nerve terminals, microglia, and astrocytes, modulating glial activity and contributing to pain hypersensitivity [5].

Microglia and astrocytes play distinct roles in pain modulation. Microglia release mediators that influence neuronal activity and nociceptor sensitization, while astrocytes regulate synaptic activity through the release of glutamate, D-serine, and ATP. Astrocytic glutamate transporters, such as GLT-1, buffer synaptic glutamate to prevent excessive postsynaptic receptor activation. However, GLT-1 is downregulated after injury, disrupting synaptic glutamate homeostasis and increasing dorsal horn excitability, which contributes to persistent pain. Key cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α), play critical roles in pain hypersensitivity. IL-1β modulates microglia, astrocytes, and neurons, facilitating NMDA receptor phosphorylation and altering synaptic strength. TNF-α, upregulated pain pathways after injury, enhances NMDA and AMPA receptor activity, further contributing to hyperalgesia. These interactions highlight the importance of glia-derived pro-inflammatory cytokines in pain modulation. Chronic pain in inflammatory conditions, such as inflammatory bowel disease and rheumatoid arthritis, underscores the immune system's role in neuronal sensitization. The resolution of tissue immune responses often leads to pain reduction, emphasizing the intricate connection between immune activation and pain pathways. Understanding these mechanisms provides valuable insights for developing targeted therapies to alleviate pain in inflammatory and chronic conditions [5].



Figure 3: Pain and Immune system.

Pain Management Categories:

Nonopioid Analgesic Agents

Acetaminophen (paracetamol) is utilized for the management of mild to moderate pain, as well as an adjunctive therapy for moderate to severe pain, and for the temporary reduction of fever. However, its use is not recommended for neuropathic pain due to a lack of documented efficacy [6][7][8]. Nonsteroidal anti-inflammatory drugs (NSAIDs) are employed for mild to moderate pain, particularly when inflammation is present, and for fever reduction. Similar to acetaminophen, NSAIDs lack evidence supporting their use in neuropathic pain management. Certain NSAIDs, such as aspirin, have additional indications unrelated to pain, such as the secondary prevention of myocardial infarction, though these applications fall outside the scope of this discussion [8][9]. Antidepressant medications, specifically selective serotonin and norepinephrine reuptake inhibitors (SNRIs) like duloxetine, and tricyclic antidepressants (TCAs) such as amitriptyline, have demonstrated efficacy in treating various neuropathic pain conditions and are recommended as first-line therapies [10]. Beyond their primary indications for psychiatric disorders, including major depressive disorder and generalized anxiety disorder, these medications are also indicated for conditions such as fibromyalgia and chronic musculoskeletal pain. Additionally, antidepressants are recommended for the prophylactic treatment of migraine and tension-type headaches, with amitriptyline being particularly noted. These pharmacological agents appear to be more effective in patients experiencing comorbid depressive symptoms and pain than in those with pain alone [8][10]. Antiepileptic drugs, known for their analgesic properties, function by reducing neurotransmitter release or neuronal firing. Gabapentin and pregabalin are among the most commonly prescribed antiepileptics for pain management. Gabapentin is indicated for postherpetic neuralgia in adults and neuropathic pain, while pregabalin is used for neuropathic pain associated with diabetic peripheral neuropathy, spinal cord injury, postherpetic neuralgia, and fibromyalgia. Oxcarbazepine and carbamazepine are specifically utilized for trigeminal or glossopharyngeal neuralgia [8]. Local anesthetics, such as lidocaine, are also employed in pain management, with FDA approval for postherpetic neuralgia and recommendations for peripheral neuropathic pain [8][11].

Opioid Agents

Opioids, a diverse class of medications structurally related to natural alkaloids derived from the opium poppy (*Papaver somniferum*), are recognized as the most potent and widely used agents for severe pain management [12][13]. However, their use remains highly controversial due to the risks of addiction, tolerance, and adverse effects [14]. While opioids are indicated for both acute and chronic pain, the Centers for Disease Control and Prevention (CDC) guidelines emphasize that they should only be prescribed when the anticipated benefits for pain relief and functional improvement outweigh the risks. Clinicians are advised to prescribe opioids at the lowest effective dose and for the shortest duration necessary to manage severe pain [15][16][17][18].

Mechanism of Action

Nonopioid Analgesic Agents

The precise mechanism of action of acetaminophen (paracetamol) remains incompletely understood. Although it is occasionally classified alongside nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen lacks anti-inflammatory properties and does not bind to the active sites of cyclooxygenase (COX) enzymes, specifically COX-1 or COX-2. A proposed hypothesis suggests that acetaminophen may inhibit a variant of COX-1, referred to as COX-3, though this mechanism has not been confirmed in human studies. Despite this uncertainty, the drug is believed to reduce prostaglandin synthesis in the central nervous system by diminishing COX pathway activity, thereby inducing analgesia through serotonergic inhibitory pathways and antipyresis via the hypothalamic heat-regulating center [5][7][19][20]. Nonsteroidal anti-inflammatory drugs (NSAIDs) primarily function by inhibiting the cyclooxygenase enzyme, thereby suppressing prostaglandin synthesis. These drugs are categorized based on their chemical structure and selectivity. Classes include acetylated salicylates (e.g., aspirin), non-acetylated salicylates (e.g., diflunisal), propionic acids (e.g., ibuprofen, naproxen), acetic acids (e.g., indomethacin, diclofenac), anthranilic acids (e.g., meclofenamate, mefenamic acid), enolic acids (e.g., meloxicam, piroxicam), naphthylalanine (e.g., nabumetone), and selective COX-2 inhibitors (e.g., celecoxib, etoricoxib). Most NSAIDs non-selectively inhibit both COX isoforms (COX-1 and COX-2), while others, such as aspirin and coxibs, exhibit higher affinity for one isoform, resulting in varying degrees of anti-inflammatory, analgesic, and antipyretic effects. For instance, low-dose aspirin primarily exerts an antiplatelet effect, whereas higher doses demonstrate analgesic properties [9][21][22].



Figure 4: Regions within cerebral cortex associated with pain.



Figure 5: Arachidonic acid Pathway and COX Enzymes.

Antidepressant medications, including tricyclic antidepressants (TCAs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs), function by inhibiting the reuptake of serotonin and noradrenaline. This action enhances the descending inhibitory pain pathways within the central nervous system. Additionally, TCAs exert effects on cholinergic, histamine, beta2 adrenergic, opioid, and N-methyl-D-aspartate (NMDA) receptors, as well as sodium channels, further contributing to their analgesic properties [8][10][23]. Antiepileptic medications such as gabapentin and pregabalin act as ligands for the αδ subunit of voltage-dependent calcium channels, which are often overexpressed in individuals with neuropathic pain. By reducing calcium-dependent release of excitatory neurotransmitters, these agents decrease neuronal excitability, thereby alleviating pain [8][24]. Local anesthetics, including lidocaine, stabilize neuronal membranes by inhibiting sodium ion channels on the internal surface of nerve cell membranes. This action impedes the conduction of pain signals through nerve impulses at the site of administration, without inducing systemic effects [25].

Opioid Agents

The majority of clinically relevant opioids primarily act as agonists at the mu-opioid receptors, though they may also interact with other receptor types, including kappa, delta, and sigma receptors. All these receptors are G protein-coupled and mediate various physiological effects, such as spinal and supraspinal analgesia. Opioids exert their effects through both presynaptic and postsynaptic mechanisms. Presynaptically, they inhibit calcium channels on nociceptive afferent nerves, thereby reducing the release of neurotransmitters such as substance P and glutamate. Postsynaptically, opioids enhance potassium channel activity, leading to membrane hyperpolarization and an increased threshold for action potential generation, which further suppresses nociceptive neurotransmission [13][18].

Administration

Nonopioid Analgesic Agents

Acetaminophen (paracetamol) is administered at a recommended dose of 650 mg to 1000 mg every 4 to 6 hours for adults, with a maximum daily limit of 4 grams. For pediatric patients, the dosage is 15 mg/kg every 6 hours, not exceeding 60 mg/kg/day [27]. This medication is available in various formulations, including oral tablets, capsules, syrups, oral solutions, suspensions, and rectal suppositories, as well as intravenous administration [7]. Nonsteroidal anti-inflammatory drugs (NSAIDs) encompass over 20 commercially available agents, with the choice of drug influenced by factors such as patient comorbidities and bleeding risk. Individual responses to NSAIDs vary, and the underlying mechanisms for these differences remain only partially understood. Consequently, dosing is specific to each drug, with the general recommendation to prescribe the lowest effective dose for the shortest duration. Commonly used NSAIDs and their respective analgesic and anti-inflammatory doses include:

- Aspirin (acetylsalicylic acid): 325 to 650 mg every 4 to 6 hours, with a maximum daily dose of 4000 mg. It is available in oral (caplets, capsules, tablets) and rectal (suppository) forms.
- Diclofenac: 50 mg every 8 hours, not exceeding 150 mg/day. It is administered orally (tablets, capsules, packets), intravenously, topically (creams, gels, patches, solutions), or ophthalmically.
- Ibuprofen: 400 mg every 4 to 6 hours, with a maximum daily dose of 3200 mg for acute pain or 2400 mg for chronic pain. It is available orally (capsules, tablets, suspensions) and intravenously.
- Indomethacin: Immediate-release formulations are dosed at 25 to 50 mg every 8 to 12 hours, while controlled-release formulations are administered at 75 mg once or twice daily, not exceeding 150 mg/day. It is available orally (capsules, suspensions), intravenously, and rectally (suppositories).
- Meloxicam: 7.5 to 15 mg once daily, with a maximum daily dose of 15 mg. It is administered orally (tablets, capsules, suspensions) or intravenously.
- Naproxen: 250 to 500 mg every 12 hours (naproxen base) or 275 to 550 mg every 12 hours (naproxen sodium), with maximum daily doses of 1250 mg (acute) or 1000 mg (chronic) for naproxen base and 1375 mg (acute) or 1100 mg (chronic) for naproxen sodium. It is available only in oral formulations (capsules, suspensions, tablets).
- Celecoxib: 200 mg daily or 100 mg every 12 hours, with a maximum daily dose of 400 mg. It is administered orally in capsule form [6][7][28].

Among antidepressant medications, tricyclic antidepressants (TCAs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs) such as amitriptyline and duloxetine are well-documented for their analgesic effects. Amitriptyline is dosed at 25 to 150 mg orally once daily or in divided doses, with maximum single and daily doses of 75 mg and 150 mg, respectively. Caution is advised for patients aged 65 years or older, with daily doses not exceeding 75 mg. Duloxetine is administered at 60 to 120 mg orally once daily or in divided doses, with a maximum daily dose of 120 mg [8][29]. Antiepileptic medications such as gabapentin and pregabalin are also utilized for pain management. Gabapentin is dosed at 300 to 600 mg orally three times daily, with a maximum daily dose of 1800 mg for postherpetic neuralgia or 3600 mg for other conditions. Pregabalin is administered at 300 to 600 mg/day orally in two divided doses [8]. Local anesthetics, including lidocaine, are available in various formulations. Lidocaine patches are applied at concentrations of 1.8% or 5%, with a recommendation of 1-3 patches applied to intact skin for up to 12 hours daily. Other formulations include topical solutions, creams, gels, ointments, and lotions [8].

Opioid Agents

Opioids are available in diverse dosage forms and routes of administration, including oral, transdermal, intramuscular, intravenous, subcutaneous infusion, rectal, epidural, intrathecal, intranasal, and transmucosal [18][31]. The selection of route, dosage range, and formulation depends on multiple factors. For comprehensive guidance, the American Pain Society guidelines provide detailed recommendations.

Adverse Effects

Nonopioid Analgesic Agents

Acetaminophen (paracetamol) is generally considered a safe and effective medication when used as directed. However, its adverse effects vary depending on the route of administration. When administered orally or rectally, potential adverse effects include rash or hypersensitivity reactions such as toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and Stevens-Johnson syndrome. Hematological effects may include anemia, leukopenia, neutropenia, and pancytopenia. Nephrotoxicity, metabolic disturbances, and electrolyte imbalances such as decreased serum bicarbonate, hyponatremia, hypocalcemia, hyperammonemia, hyperchloremia, hyperuricemia, hyperglycemia, and hyperbilirubinemia have also been reported. Elevated alkaline phosphatase levels may occur as well [6][7][28]. Intravenous administration of acetaminophen is associated with nausea, vomiting, pruritus, constipation, and abdominal pain [7]. In pediatric patients, regardless of the route of administration, the most frequently reported adverse reactions include nausea, vomiting, agitation, constipation, pruritus, and atelectasis.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a wide range of adverse effects. Gastrointestinal complications include nausea, anorexia, dyspepsia, abdominal pain, ulcers, gastrointestinal hemorrhage, perforation, constipation, and diarrhea. Cardiovascular effects may encompass hypertension, reduced efficacy of antihypertensive medications, myocardial infarction, stroke, and thromboembolic events, particularly with selective COX-2 inhibitors. NSAIDs also inhibit platelet activation, increasing the risk of bruising and hemorrhage. Renal adverse effects include salt and water retention, deterioration of kidney function, edema, reduced efficacy of diuretics, decreased urate excretion, hyperkalemia, and

analgesic nephropathy. Central nervous system effects may involve headache, dizziness, vertigo, confusion, depression, lowered seizure threshold, and hyperventilation, particularly with salicylates. Hypersensitivity reactions such as vasomotor rhinitis, asthma, urticaria, flushing, hypotension, and shock have also been documented. Hepatotoxicity is another potential risk [9][8][22]. For a comprehensive list of adverse effects associated with specific NSAIDs, refer to the relevant StatPearls articles.

Antidepressant medications, including amitriptyline and duloxetine, are associated with distinct adverse effects. Amitriptyline may cause altered mental status, arrhythmias, constipation, decreased libido, dizziness, drowsiness, dry mouth, headache, hyperhidrosis, increased risk of suicidal thoughts, micturition disorders such as urinary retention, nausea, orthostatic hypotension, tremor, and weight gain. Duloxetine is linked to nausea, headache, dry mouth, somnolence, dizziness, abdominal pain, constipation, increased blood pressure, and an elevated risk of suicidal thoughts [8][10][29]. Antiepileptic medications such as gabapentin and pregabalin also carry notable adverse effects. Gabapentin commonly causes dizziness, somnolence, ataxia, peripheral edema, and confusion. More severe reactions include anaphylaxis, suicidality, depression, fever, infection, Stevens-Johnson syndrome, angioedema, erythema multiforme, and rhabdomyolysis [30][32]. Pregabalin is associated with dizziness, somnolence, headache, peripheral edema, nausea, weight gain, disorientation, blurred vision, and an increased risk of suicidal thoughts [8]. Local anesthetics, such as lidocaine, may cause application-site pain, pruritus, erythema, and skin irritation [8].

Opioid Agents

Opioids are associated with a broad spectrum of systemic adverse effects. These include dysphoria or euphoria, sedation, constipation, nausea and vomiting, cough suppression, miosis, and histamine release, which may manifest as urticaria, pruritus, hypotension, and tachycardia. Endocrine system suppression, cardiovascular disorders such as bradycardia, and respiratory depression are also potential risks. Skeletal muscle rigidity may occur, particularly with high doses. Chronic use of opioids can lead to tolerance, physical dependence, and opioid-induced hyperalgesia or allodynia [18][13].

Contraindications

Nonopioid Analgesic Agents

Acetaminophen (paracetamol) is contraindicated in individuals with hypersensitivity to the drug or any of its excipients, severe hepatic impairment, or severe active hepatic disease. There is ongoing debate among experts regarding whether hepatic impairment should remain a contraindication, as it may result in reduced levels of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) [7][33]. Notably, pregnancy is not a contraindication for acetaminophen use. Nonsteroidal anti-inflammatory drugs (NSAIDs) are primarily contraindicated in cases of hypersensitivity. However, several conditions necessitate avoidance, temporary suspension, or cautious use, including age over 50 years with a family history of gastrointestinal (GI) disease or bleeding, previous GI complications related to NSAID use (e.g., gastritis), peptic ulcer disease, personal history of GI bleeding, uncontrolled hypertension, renal disease, irritable bowel syndrome, inflammatory bowel disease, recent coronary artery bypass surgery, gastric bypass surgery, and pregnancy (third trimester). Additional conditions requiring caution include stroke, transient ischemic attack, myocardial infarction, and congestive heart failure, though these exclusions do not apply to aspirin [8][22].

Antidepressant medications such as amitriptyline and duloxetine have specific contraindications. Amitriptyline is contraindicated in cases of hypersensitivity, concurrent use or recent administration (within 14 days) of monoamine oxidase inhibitors (MAOIs), coadministration with cisapride, recent myocardial infarction, arrhythmias, acute heart failure, and severe liver impairment. Duloxetine is contraindicated in hypersensitivity reactions, liver impairment, severe renal failure (e.g., CrCl <30 mL/minute) or end-stage renal disease (ESRD), concurrent use or recent administration (within 14 days) of MAOIs, concomitant use of linezolid, thioridazine, methylene blue, or potent CYP1A2 inhibitors, and uncontrolled narrow-angle glaucoma. Caution is advised in patients with hypertension or cardiac disease [8][10][23]. Antiepileptic medications, including gabapentin and pregabalin, are contraindicated only in cases of hypersensitivity to the drug or its excipients. However, dose adjustments are necessary for patients with compromised renal function [8]. Local anesthetics such as lidocaine are contraindicated in patients with a history of hypersensitivity to amide-type local anesthetics or any of their excipients. Additionally, lidocaine patches should only be applied to intact skin [25].

Opioid Agents

Opioids are contraindicated in patients with severe respiratory instability, acute mental instability, or a high risk of suicidal behavior. Specific contraindications for methadone include a QTc interval exceeding 500 milliseconds. Other contraindications include a family or personal history of substance abuse, intolerance or serious adverse effects to structurally similar opioids, and lack of efficacy with previous opioid use. Renal or hepatic impairment may also contraindicate certain opioids, depending on their metabolism and excretion pathways [18].

Monitoring

Nonopioid Analgesic Agents

Acetaminophen (paracetamol) is generally regarded as a safe medication when used appropriately. Toxicity typically occurs at doses exceeding 150 mg/kg, resulting in a therapeutic index estimated to be around 10 [34]. For nonsteroidal anti-inflammatory drugs (NSAIDs), routine monitoring is not required for acute administration in healthy patients. However, patients on chronic NSAID therapy (e.g., for rheumatoid arthritis) and those at increased risk of NSAID toxicity (e.g., individuals with liver or renal disease) should undergo periodic evaluations, including complete blood count (CBC), renal function tests, and hepatic function tests as a baseline. Additional tests may be warranted based on clinical suspicion and findings [9].

Antidepressant Medications

Amitriptyline requires an adequate trial period of 6 to 8 weeks to assess efficacy. If patients achieve pain relief but experience intolerable adverse effects, switching to another tricyclic antidepressant (TCA) such as imipramine or nortriptyline

may be considered. Administering the dose at bedtime can help manage concurrent insomnia or daytime somnolence. Periodic monitoring should include heart rate, blood pressure, electrocardiogram (ECG) for older adults or those with preexisting cardiac conditions, blood glucose levels, weight and body mass index (BMI), and electrolyte panels for high-risk populations. Additionally, patients should be evaluated for suicidal ideation and mood instability [8][10][29]. For duloxetine, a 6 to 8-week trial period is also recommended. Monitoring should include periodic blood pressure measurements, particularly in hypertensive patients, liver and renal function tests as clinically indicated, blood glucose and HbA1c levels in diabetic patients, and serum sodium levels in high-risk populations. Clinicians should also assess patients for suicidal ideation [8][10][29].

Antiepileptic Medications

Baseline creatinine levels should be evaluated before and during treatment for patients prescribed gabapentin or pregabalin. Additionally, periodic screenings for depression, behavioral changes, and suicidality are essential [32][35].

Local Anesthetics

Lidocaine, due to its narrow therapeutic index, requires careful monitoring in patients with severe hepatic impairment, those receiving prolonged infusions, or individuals with broken or inflamed skin to prevent elevated plasma levels. Although rare, cases of methemoglobinemia have been documented with local anesthetic use, particularly with patch administration. Signs of methemoglobinemia include cyanotic skin discoloration and abnormal blood coloration [25].

Opioid Agents

Patients on opioid therapy should undergo periodic evaluations to assess pain control and physical examination findings. Follow-ups should focus on vital signs, signs of misuse, abuse, or addiction, respiratory and mental status, and symptoms of hypogonadism or hypoadrenalism [18].

Toxicity

Nonopioid Analgesic Agents

Acetaminophen (paracetamol) toxicity typically occurs at doses exceeding 7.5 g/day to 10 g/day or 140 mg/kg, with rare instances at doses below 150 mg/kg for adults or 200 mg/kg for children. Excessive ingestion can lead to severe liver damage, potentially necessitating a liver transplant or resulting in death. Although acetaminophen poisoning is more frequently observed in children, adults often present with more severe and fatal outcomes [6][27][36][37]. In cases of acute overdose, acetaminophen serum levels should be measured between 4 to 24 hours post-ingestion to determine the appropriate treatment. The Rumack-Matthew Nomogram is utilized to assess toxic levels, with a serum concentration exceeding 140 mcg/mL at 4 hours indicating the need for N-acetylcysteine (NAC) therapy. Activated charcoal, which binds acetaminophen effectively, may be administered within the first hour of ingestion but is contraindicated in patients with altered consciousness or a high risk of airway obstruction [27][38][39][40]. Nonsteroidal anti-inflammatory drugs (NSAIDs) generally result in asymptomatic or mild, self-limiting gastrointestinal symptoms in cases of acute overdose. However, severe complications may occur, including confusion, headache, nystagmus, drowsiness, blurred vision, diplopia, tinnitus, convulsions, metabolic acidosis, acute renal or liver failure, gastrointestinal bleeding, and coma [9][41].

Antidepressant Medications

Amitriptyline toxicity can manifest with severe symptoms such as confusion, transient visual hallucinations, mydriasis, agitation, dysrhythmias, severe hypotension, convulsions, hyperreflexia, stupor, drowsiness, muscle rigidity, vomiting, hypothermia, hyperpyrexia, coma, and death. Electrocardiogram (ECG) abnormalities, particularly changes in QRS axis or width, are significant indicators of tricyclic antidepressant (TCA) toxicity. Other ECG findings may include prolonged PR interval, ST-T wave changes, ventricular tachycardia, and fibrillation. However, the absence of these abnormalities does not exclude TCA poisoning [8][10][29]. Duloxetine toxicity may present serotonin syndrome, somnolence, syncope, tachycardia, seizures, autonomic instability, diarrhea, vomiting, and coma. No specific antidote exists for duloxetine overdose, though cyproheptadine and cooling measures may be considered in cases of serotonin syndrome [42].

Antiepileptic Medications

Gabapentin does not typically pose a risk of overdose or addiction compared to other pain management medications, such as opioids. However, it may enhance the euphoric effects of opioids [32]. Pregabalin overdose is poorly documented, with the highest accidental dose reported in clinical research being 8000 mg. Similar to gabapentin, there is no specific antidote for pregabalin toxicity [35].

Local Anesthetics

Lidocaine toxicity generally occurs at blood concentrations exceeding 5 mcg/mL. Symptoms progress from slurred speech, tinnitus, paresthesias, and dizziness to loss of consciousness, seizures, cardiac arrhythmias, and cardiorespiratory arrest. Management is supportive, including oxygen, intravenous fluids, and inotropes. In cases of refractory cardiovascular collapse, intravenous lipid emulsion is indicated [25].

Opioid Agents

Opioid overdose can be fatal due to severe respiratory depression. Clinicians should suspect opioid toxicity in patients presenting with altered mental status, bradypnea, and constricted pupils. Naloxone, administered intravenously, intramuscularly, or intranasally, is indicated for respiratory depression. Given its short duration of action (30 to 60 minutes), continuous intravenous infusion is necessary in cases of long-acting opioid overdose [18][43].

Enhancing Healthcare Teams Outcomes:

Effective pain management necessitates a collaborative, multidisciplinary healthcare approach to ensure accurate and individualized pain control for patients. Given that adverse effects are more prevalent in individuals with specific comorbidities, follow-up care must include comprehensive history-taking and physical examinations to identify potential side effects or signs of addiction and misuse. This proactive monitoring is essential to mitigate risks and optimize therapeutic outcomes. Patient education plays a pivotal role in pain management. Healthcare providers must attentively assess patients' symptoms and concerns to deliver optimal care while minimizing systemic adverse effects. To detect and prevent drug misuse, various strategies can be employed, including state prescription drug monitoring programs, validated assessment surveys, adherence checklists, motivational counseling, urine drug screening, and verification of dosage forms. These tools help ensure that patients use medications appropriately and safely. Interprofessional collaboration is fundamental to achieving successful pain management outcomes. By integrating the expertise of physicians, pharmacists, nurses, and other healthcare professionals, a cohesive approach can be developed to address the complex needs of patients experiencing pain. Pharmacists, for instance, can provide valuable insights into medication selection, dosing, and potential drug interactions, while nurses can monitor patients for adverse effects and provide ongoing support. Psychologists or counselors may assist in addressing underlying psychological factors contributing to pain, such as anxiety or depression. Through such teamwork, healthcare providers can tailor pain management strategies to individual patient needs, ensuring maximum therapeutic benefit while minimizing risks. This collaborative model not only enhances patient safety and satisfaction but also reduces the likelihood of medication misuse and addiction. Ultimately, a well-coordinated, interprofessional approach to pain management fosters better clinical outcomes and improves the overall quality of care for patients.

Conclusion:

Pain management is a complex and multifaceted aspect of healthcare that requires a comprehensive, patient-centered approach. The IASP defines pain as an unpleasant sensory and emotional experience, and while debates continue regarding its definition, the classification of pain management agents remains well-established. Nonopioid analgesics, such as acetaminophen, NSAIDs, antidepressants, and antiepileptics, are foundational for managing mild to moderate pain and neuropathic conditions. These agents work through various mechanisms, including inhibition of prostaglandin synthesis, modulation of neurotransmitter activity, and stabilization of neuronal membranes. However, their use is not without risks, as they can cause adverse effects such as gastrointestinal complications, hepatotoxicity, and metabolic disturbances. Opioids, while highly effective for severe pain, are associated with significant risks, including addiction, tolerance, and life-threatening adverse effects such as respiratory depression. The Centers for Disease Control and Prevention (CDC) guidelines emphasize that opioids should only be prescribed when the benefits outweigh the risks, at the lowest effective dose, and for the shortest duration necessary. This cautious approach is essential to mitigate the opioid crisis and ensure patient safety. Effective pain management extends beyond pharmacological interventions. It requires a multidisciplinary approach involving physicians, pharmacists, nurses, and mental health professionals. Pharmacists play a critical role in medication selection and monitoring, while nurses provide ongoing patient support and monitoring for adverse effects. Mental health professionals address underlying psychological factors, such as anxiety and depression, which often coexist with chronic pain. Patient education is equally important, as it empowers individuals to understand their treatment plans, recognize signs of adverse effects, and adhere to prescribed therapies. Monitoring and follow-up are essential components of pain management, particularly for patients on chronic therapy or those at risk of adverse effects. Tools such as state prescription drug monitoring programs, urine drug screening, and adherence checklists help detect and prevent misuse. Additionally, periodic evaluations of pain control, physical examination findings, and mental status are crucial for optimizing outcomes. In conclusion, pain management is a dynamic and evolving field that requires a balanced approach to efficacy and safety. By integrating pharmacological treatments with interprofessional collaboration and patient education, healthcare providers can improve pain management outcomes, enhance patient safety, and reduce the risks associated with analgesic use.

References:

1. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl. 1986;3:S1-226.
2. Aydede M. Does the IASP definition of pain need updating? Pain Rep. 2019 Sep-Oct;4(5):e777.
3. Alcock MM. Defining pain: past, present, and future. Pain. 2017 Apr;158(4):761-762.
4. Cohen M, Quintner J, van Rysewyk S. Reconsidering the International Association for the Study of Pain definition of pain. Pain Rep. 2018 Mar;3(2):e634.
5. Di Maio, G., Villano, I., Ilardi, C. R., Messina, A., Monda, V., Iodice, A. C., Porro, C., Panaro, M. A., Chieffi, S., Messina, G., Monda, M., & La Marra, M. (2023). Mechanisms of Transmission and Processing of Pain: A Narrative Review. *International Journal of Environmental Research and Public Health*, *20*(4), 3064. https://doi.org/10.3390/ijerph20043064
6. Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014 Jan-Feb;71(1):11-23.
7. Kholili, U., Nugroho, Y. H., Sugihartono, T., Nusi, I. A., & Setiawan, P. B. (2023). Liver injury associated with Acetaminophen: A Review. *Research Journal of Pharmacy and Technology*, *16*(4), 2006-2012.
8. Finnerup NB. Nonnarcotic Methods of Pain Management. N Engl J Med. 2019 Jun 20;380(25):2440-2448.
9. Ghlichloo I, Gerriets V. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
10. Attal N. Pharmacological treatments of neuropathic pain: The latest recommendations. Rev Neurol (Paris). 2019 Jan-Feb;175(1-2):46-50.

11. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73.
12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Nov 24, 2020. Opioids, Opioid Antagonists.
13. Zöllner C, Stein C. Opioids. Handb Exp Pharmacol. 2007;(177):31-63.
14. Smith HS. Opioids and neuropathic pain. Pain Physician. 2012 Jul;15(3 Suppl):ES93-110.
15. Guy GP, Zhang K, Bohm MK, Losby J, Lewis B, Young R, Murphy LB, Dowell D. Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017 Jul 07;66(26):697-704.
16. Chakote K, Guggenheimer J. Implications of use of opioid-containing analgesics for palliation of acute dental pain. J Opioid Manag. 2019 Jan/Feb;15(1):35-41.
17. Aubrun F, Nouette-Gaulain K, Fletcher D, Belbachir A, Beloeil H, Carles M, Cuvillon P, Dadure C, Lebuffe G, Marret E, Martinez V, Olivier M, Sabourdin N, Zetlaoui P. Revision of expert panel's guidelines on postoperative pain management. Anaesth Crit Care Pain Med. 2019 Aug;38(4):405-411.
18. Cohen B, Ruth LJ, Preuss CV. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 29, 2023. Opioid Analgesics.
19. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
20. Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):85-7.
21. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med. 1991 Jun 13;324(24):1716-25.
22. Munir MA, Enany N, Zhang JM. Nonopioid analgesics. Med Clin North Am. 2007 Jan;91(1):97-111.
23. Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin. 2018 May;68(3):182-196.
24. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic pain. Nat Rev Dis Primers. 2017 Feb 16;3:17002.
25. Silva, A., Mourão, J., & Vale, N. (2023). A Review of the Lidocaine in the Perioperative Period. *Journal of Personalized Medicine*, *13*(12), 1699.
26. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008 Mar;11(2 Suppl):S133-53.
27. Agrawal S, Khazaeni B. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 9, 2023. Acetaminophen Toxicity.
28. McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. Long-term adverse effects of paracetamol - a review. Br J Clin Pharmacol. 2018 Oct;84(10):2218-2230.
29. Wright ME, Rizzolo D. An update on the pharmacologic management and treatment of neuropathic pain. JAAPA. 2017 Mar;30(3):13-17.
30. Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013 Mar;36(3):237-51.
31. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13.
32. Milani, D. A. Q., & Davis, D. D. (2023). Pain management medications. In *StatPearls [Internet]*. StatPearls Publishing.
33. Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment? Br J Clin Pharmacol. 2016 Feb;81(2):210-22.
34. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006 Fall-Winter;12(3-4):250-75.
35. Shen, X., Chen, X., He, Y., Xu, H., & Zhu, J. (2023). Efficacy and safety of pregabalin in eye pain: A systematic review. *Medicine*, *102*(6), e32875.
36. Penna A, Buchanan N. Paracetamol poisoning in children and hepatotoxicity. Br J Clin Pharmacol. 1991 Aug;32(2):143-9.
37. Wong A, Graudins A. Risk prediction of hepatotoxicity in paracetamol poisoning. Clin Toxicol (Phila). 2017 Sep;55(8):879-892.
38. Yeates PJ, Thomas SH. Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. Br J Clin Pharmacol. 2000 Jan;49(1):11-4.
39. Levy G, Houston JB. Effect of activated charcoal on acetaminophen absorption. Pediatrics. 1976 Sep;58(3):432-5.
40. Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2018 Feb 23;2(2):CD003328.
41. Hunter LJ, Wood DM, Dargan PI. The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open Access Emerg Med. 2011;3:39-48.
42. Dhaliwal JS, Spurling BC, Molla M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 29, 2023. Duloxetine.
43. Didik, S., Golosova, D., Xu, B., & Staruschenko, A. (2023). Opioids and the Kidney: A Compendium. *Kidney360*, 10-34067.